ArticleScientific reports2026
Integrated expression profiling reveals molecular crosstalk between CFTR, FASN, FRAP (mTOR), and BANK1 in hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy characterised by molecular heterogeneity and poor prognosis. The purpose of this study was to determine differences in the expression of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Fatty Acid Synthase (FASN), FKBP12-rapamycin-associated protein (FRAP; mTOR), and B-cell scaffold protein with ankyrin repeats 1 (BANK1) between HCC patients and controls. A total of 200 blood samples (100 from HCC patients and 100 from controls) were analysed using Reverse Transcription Polymerase Chain Reaction (RT-PCR), with Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as an internal control. The results demonstrated significant upregulation of FASN and FRAP (mTOR) (p < 0.0001) and downregulation of CFTR and BANK1 (p < 0.0001), suggesting potential oncogenic and tumour-suppressive roles, respectively. Gene expression levels also differed significantly across Stages I, II, III, and IV. The Ct values for BANK1 were higher than those for CFTR, FASN, and FRAP (mTOR). Because the expression measurements for the four genes were obtained from blood rather than tumour parenchyma, these findings were not interpreted as direct evidence of gene expression within tumour tissue. Survival analysis using a public dataset revealed that dysregulation of these genes was associated with lower survival rates. In silico pathway analysis demonstrated complex interactions among the four genes, linking them to metabolic regulation, immune signalling, and cellular proliferation pathways. Overall, the integrated network involving CFTR, FASN, FRAP (mTOR), and BANK1 may have potential as a novel prognostic marker by reflecting combined metabolic and immune pathway activity. A combined four-gene logistic regression model demonstrated promising discriminative performance in the present cohort (AUC = 0.89). However, this finding requires validation in independent cohorts before any diagnostic application can be considered.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.